GMAB earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E 21.61. Updated 2026-07-23.
Genmab (GMAB) Research Hub
Genmab (GMAB) trades on NASDAQ, DK in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 32.47 USD (-1.73%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 21.61, market cap 17.82B. This hub links to the full technical, earnings and options research available for GMAB.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, DK |
| Last close | 32.47 USD (-1.73%) |
| 52-week range | 24.51 USD – 34.66 USD |
| Trend regime | Range |
| 14-day RSI | 56.4 (Bullish) |
| Trailing P/E | 21.61 |
| Market cap | 17.82B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for GMAB
Covered Call on GMAB: how it works, illustrative setup around the real 32.47 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on GMAB: how it works, illustrative setup around the real 32.47 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on GMAB: how it works, illustrative setup around the real 32.47 USD price, max profit/loss, breakeven and when to use it. Educational.
GMAB technical analysis: range, last 32.47 USD, RSI 56.4, 52w range 24.51 USD–34.66 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is GMAB in?
Genmab (GMAB) is classified under Healthcare (Biotechnology), listed on NASDAQ, DK.
Is GMAB in an uptrend or downtrend?
As of 2026-09-11, GMAB is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is GMAB's trailing P/E ratio?
GMAB's trailing P/E is 21.61, with a market cap of 17.82B. See the earnings research page for full valuation detail.
When does GMAB next report earnings?
GMAB is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of 0.35 USD.